Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 984-991

  Markota, Matej ^a,b   Sin, Jessica ^a   Pantazopoulos, Harry ^a,b   Jonilionis, Rebecca ^a   Berretta, Sabina ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Amygdala; Bipolar disorder; Dopamine beta hydroxylase; Dopamine transporter; Schizophrenia

Indexed keywords

DOPAMINE BETA MONOOXYGENASE; DOPAMINE TRANSPORTER; SEROTONIN TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

ACCESSORY BASAL NUCLEUS; AMYGDALOID NUCLEUS; ARTICLE; BASAL AMYGDALA; BIPOLAR DISORDER; BRAIN; CELLULAR PARAMETERS; CONTROLLED STUDY; CORTICAL AMYGDALA; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; HUMAN; HUMAN TISSUE; INTERCALATED CELL MASS; LATERAL AMYGDALA; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; HEALTH CARE FACILITY; METABOLISM;

AMYGDALA; BIPOLAR DISORDER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; SCHIZOPHRENIA; TISSUE BANKS;

EID: 84907359762     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu084     Document Type: Article

References (61)

1. van Os J. 'Salience syndrome' replaces 'schizophrenia' in DSM-V and ICD-11: psychiatry's evidence-based entry into the 21st century? Acta Psychiatry Scand. 2009;120: 363-372.
2. Pankow A, Knobel A, Voss M, Heinz A. Neurobiological correlates of delusion: beyond the salience attribution hypothesis. Neuropsychobiology. 2012;66: 33-43.
3. Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull. 2010;36: 472-485.
4. Berridge KC. From prediction error to incentive salience: mesolimbic computation of reward motivation. Eur J Neurosci. 2012;35: 1124-1143.
5. Morrison SE, Salzman CD. Re-valuing the amygdala. Curr Opin Neurobiol. 2010;20: 221-230.
6. Paton JJ, Belova MA, Morrison SE, Salzman CD. The primate amygdala represents the positive and negative value of visual stimuli during learning. Nature. 2006;439: 865-870.
7. Aleman A, Kahn RS. Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol. 2005;77: 283-298.
8. Roberts RC, Roche JK, Conley RR, Lahti AC. Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse. 2009;63: 520-530.
9. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000;97: 8104-8109.
10. Haber SN, Fudge JL. The interface between dopamine neurons and the amygdala: implications for schizophrenia. Schizophr Bull. 1997;23: 471-482.
11. Reynolds GP. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature. 1983;305: 527-529.
12. Salgado-Pineda P, Delaveau P, Blin O, Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol. 2005;28: 228-237.
13. Darvas M, Fadok JP, Palmiter RD. Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response. Learn Mem. 2011;18: 136-143.
14. Holt DJ, Coombs G, Zeidan MA, Goff DC, Milad MR. Failure of neural responses to safety cues in schizophrenia. Arch Gen Psychiatry. 2012;69: 893-903.
15. Murray EA, Rudebeck PH. The drive to strive: goal generation based on current needs. Front Neurosci. 2013;7: 112.
16. Dolan RJ. The human amygdala and orbital prefrontal cortex in behavioural regulation. Philos Trans R Soc Lond B Biol Sci. 2007;362: 787-799.
17. Marowsky A, Yanagawa Y, Obata K, Vogt KE. A specialized subclass of interneurons mediates dopaminergic facilitation of amygdala function. Neuron. 2005;48: 1025-1037.
18. Inglis FM, Moghaddam B. Dopaminergic innervation of the amygdala is highly responsive to stress. J Neurochem. 1999;72: 1088-1094.
19. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010;35: 4-26.
20. Sesack SR, Grace AA. Cortico-Basal Ganglia reward network: microcircuitry. Neuropsychopharmacology. 2010;35: 27-47.
21. Anderson AK, Phelps EA. Lesions of the human amygdala impair enhanced perception of emotionally salient events. Nature. 2001;411: 305-309.
22. Peck CJ, Lau B, Salzman CD. The primate amygdala combines information about space and value. Nat Neurosci. 2013;16: 340-348.
23. Escartí MJ, de la Iglesia-Vayá M, Martí- Bonmatí L, et al. Increased amygdala and parahippocampal gyrus activation in schizophrenic patients with auditory hallucinations: an fMRI study using independent component analysis. Schizophr Res. 2010;117: 31-41.
24. Melchitzky DS, Lewis DA. Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology. 2000;22: 466-472.
25. Sesack SR, Hawrylak VA, Guido MA, Levey AI. Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol. 1998;42: 171-174.
26. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci. 1995;15: 1714-1723.
27. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379: 606-612.
28. Berretta S, Pantazopoulos H, Lange N. Neuron numbers and volume of the amygdala in subjects diagnosed with bipolar disorder or schizophrenia. Biol Psychiatry. 2007;62: 884-893.
29. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry. 2010;67: 155-166.
30. García-Amado M, Prensa L. Distribution of dopamine transporter immunoreactive fibers in the human amygdaloid complex. Eur J Neurosci. 2013;38: 3589-3601.
31. Asan E. The catecholaminergic innervation of the rat amygdala. Adv Anat Embryol Cell Biol. 1998;142: 1-118.
32. Mash DC, Staley JK, Izenwasser S, Basile M, Ruttenber AJ. Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat. 2000;20: 271-280.
33. Ciliax BJ, Drash GW, Staley JK, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 1999;409: 38-56.
34. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002;52: 740-748.
35. Sadikot AF, Parent A. The monoaminergic innervation of the amygdala in the squirrel monkey: an immunohistochemical study. Neuroscience. 1990;36: 431-447.
36. Dias SJ, Zhou X, Ivanovic M, et al. Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Sci Rep. 2013;3: 2331.
37. Asan E. Ultrastructural features of tyrosine-hydroxylaseimmunoreactive afferents and their targets in the rat amygdala. Cell Tissue Res. 1997;288: 449-469.
38. Pinto A, Sesack SR. Ultrastructural analysis of prefrontal cortical inputs to the rat amygdala: spatial relationships to presumed dopamine axons and D1 and D2 receptors. Brain Struct Funct. 2008;213: 159-175.
39. Garris PA, Wightman RM. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci. 1994;14: 442-450.
40. Garris PA, Wightman RM. Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Synapse. 1995;20: 269-279.
41. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci. 2006;8: 137-142.
42. LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci. 2000;23: 155-184.
43. Johansen JP, Cain CK, Ostroff LE, LeDoux JE. Molecular mechanisms of fear learning and memory. Cell. 2011;147: 509-524.
44. Blair HT, Schafe GE, Bauer EP, Rodrigues SM, LeDoux JE. Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning. Learn Mem. 2001;8: 229-242.
45. Nieh EH, Kim SY, Namburi P, Tye KM. Optogenetic dissection of neural circuits underlying emotional valence and motivated behaviors. Brain Res. 2013;1511: 73-92.
46. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull. 2013;39: 22-32.
47. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69: 776-786.
48. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 1990;4: 2737-2744.
49. Rao JS, Kellom M, Reese EA, Rapoport SI, Kim HW. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord. 2012;136: 63-71.
50. Simeone A, Di Salvio M, Di Giovannantonio LG, Acampora D, Omodei D, Tomasetti C. The role of otx2 in adult mesencephalic- diencephalic dopaminergic neurons. Mol Neurobiol. 2011;43: 107-113.
51. Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC. Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry. 2012;3: 31.
52. Cho YT, Fudge JL. Heterogeneous dopamine populations project to specific subregions of the primate amygdala. Neuroscience. 2010;165: 1501-1518.
53. Fuxe K, Jacobsen KX, Höistad M, et al. The dopamine D1 receptor-rich main and paracapsular intercalated nerve cell groups of the rat amygdala: relationship to the dopamine innervation. Neuroscience. 2003;119: 733-746.
54. McGaugh JL. Making lasting memories: remembering the significant. Proc Natl Acad Sci U S A. 2013;110(suppl 2): 10402-10407.
55. McIntyre CK, Miyashita T, Setlow B, et al. Memoryinfluencing intra-basolateral amygdala drug infusions modulate expression of Arc protein in the hippocampus. Proc Natl Acad Sci U S A. 2005;102: 10718-10723.
56. deCampo DM, Fudge JL. Amygdala projections to the lateral bed nucleus of the stria terminalis in the macaque: comparison with ventral striatal afferents. J Comp Neurol. 2013;521: 3191-3216.
57. Somerville LH, Whalen PJ, Kelley WM. Human bed nucleus of the stria terminalis indexes hypervigilant threat monitoring. Biol Psychiatry. 2010;68: 416-424.
58. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci. 1999;877: 412-438.
59. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol. 2007;78: 133-164.
60. Gradin VB, Kumar P, Waiter G, et al. Expected value and prediction error abnormalities in depression and schizophrenia. Brain. 2011;134: 1751-1764.
61. Li Z, Richter-Levin G. Priming stimulation of basal but not lateral amygdala affects long-term potentiation in the rat dentate gyrus in vivo. Neuroscience. 2013;246: 13-21.